<PubmedArticle>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">25923158</PMID>
<DateCompleted>
<Year>2016</Year>
<Month>01</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised>
<Year>2018</Year>
<Month>12</Month>
<Day>02</Day>
</DateRevised>
<Article PubModel="Electronic">
<Journal>
<ISSN IssnType="Electronic">1735-546X</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>12</Volume>
<Issue>2</Issue>
<PubDate>
<Year>2015</Year>
<Month>Apr</Month>
<Day>29</Day>
</PubDate>
</JournalIssue>
<Title>Urology journal</Title>
<ISOAbbreviation>Urol J</ISOAbbreviation>
</Journal>
<ArticleTitle>Minimally Invasive Therapy Using Intralesional OnabotulinumtoxinA in Peyronie's Disease.</ArticleTitle>
<Pagination>
<MedlinePgn>2105-10</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">To determine the effectiveness of intralesional administration of onabotulinumtoxinA in patients with Peyronie’s disease (PD).</AbstractText>
<AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">A prospective therapeutic cohort study was undertaken in patients aged ≥ 18 years with stable PD. Intervention included one-time intralesional application of 100 U of onabotulinumtoxinA. We included 22 patients who attended the urology clinic from October 1, 2011 to June 30, 2012. Primary outcome measure was degree of curvature. Secondary outcome measures were thickness of the fibrous plaque, improvement in erectile function and pain. Erectile function was evaluated using the International Index of Erectile Function (IIEF-5) questionnaire. The Visual Analog Scale (VAS) was used to measure pain during an erection. Statistical analyses were performed by Pearson’s chi-squared test for categorical variables and student’s t-test for quantitative variables. Any P value &lt; .05 was considered statistically significant.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">The size of the fibrous plaque was reduced from 0.34 ± 0.20 to 0.27 ± 0.13 cm after treatment (P = .014). The curvature initially averaged 32.95 ± 9.21°, and improved to 25 ± 9.38° (P = .025). According to the Kelami classification, the curvature was &lt; 30° in 14 cases (63.6%) and was 30°-60° in eight cases (36.4%). At 16 weeks, the curvature was &lt; 30° in 19 cases (86.4%) and 30°-60° in three cases (13.6%). The IIEF-5 score was 16.18 ± 4.46 before treatment and 18.22 ± 4.55 after treatment (P = .002). Pain was reduced from 3.36 ± 3.48 before treatment to 1.14 ± 1.58 after treatment (P = .001).</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The administration of onabotulinumtoxinA may improve the clinical manifestations of PD resulting from fibrosis, thus improving sexual function in patients.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Muñoz-Rangel</LastName>
<ForeName>Carlos Arturo</ForeName>
<Initials>CA</Initials>
<AffiliationInfo>
<Affiliation>Department of Urology, Medical Unit of High Specialty, Specialties Hospital of the Western Medical Center, Mexican Institute of Social Security, Guadalajara 44349, Jalisco, Mexico.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Fernandez-Vivar</LastName>
<ForeName>Elieser</ForeName>
<Initials>E</Initials>
<AffiliationInfo>
<Affiliation>Department of Urology, Medical Unit of High Specialty, Specialties Hospital of the Western Medical Center, Mexican Institute of Social Security, Guadalajara 44349, Jalisco, Mexico.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Bañuelos-Gallo</LastName>
<ForeName>Ruben Alejandro</ForeName>
<Initials>RA</Initials>
<AffiliationInfo>
<Affiliation>Department of Bañuelos Radiologos, Medical Unit of High Specialty, Specialties Hospital of the Western Medical Center, Mexican Institute of Social Security, Guadalajara 44349, Jalisco, Mexico.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Gonzalez-Ojeda</LastName>
<ForeName>Alejandro</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Department of Research Unit in Clinical Epidemiology, Medical Unit of High Specialty, Specialties Hospital of the Western Medical Center, Mexican Institute of Social Security, Guadalajara 44349, Jalisco, Mexico.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Macias-Amezcua</LastName>
<ForeName>Michel Dassaejv</ForeName>
<Initials>MD</Initials>
<AffiliationInfo>
<Affiliation>Department of Research Unit in Clinical Epidemiology, Medical Unit of High Specialty, Specialties Hospital of the Western Medical Center, Mexican Institute of Social Security, Guadalajara 44349, Jalisco, Mexico.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Chavez-Tostado</LastName>
<ForeName>Mariana</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Department of Research Unit in Clinical Epidemiology, Medical Unit of High Specialty, Specialties Hospital of the Western Medical Center, Mexican Institute of Social Security, Guadalajara 44349, Jalisco, Mexico.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ramirez-Campos</LastName>
<ForeName>Kenia Militzi</ForeName>
<Initials>KM</Initials>
<AffiliationInfo>
<Affiliation>Department of Research Unit in Clinical Epidemiology, Medical Unit of High Specialty, Specialties Hospital of the Western Medical Center, Mexican Institute of Social Security, Guadalajara 44349, Jalisco, Mexico.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ramirez-Arce</LastName>
<ForeName>Anais del Rocio</ForeName>
<Initials>Adel R</Initials>
<AffiliationInfo>
<Affiliation>Department of Research Unit in Clinical Epidemiology, Medical Unit of High Specialty, Specialties Hospital of the Western Medical Center, Mexican Institute of Social Security, Guadalajara 44349, Jalisco, Mexico.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Cortes-Lares</LastName>
<ForeName>Jose Antonio</ForeName>
<Initials>JA</Initials>
<AffiliationInfo>
<Affiliation>Department of Research Unit in Clinical Epidemiology, Medical Unit of High Specialty, Specialties Hospital of the Western Medical Center, Mexican Institute of Social Security, Guadalajara 44349, Jalisco, Mexico.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Fuentes-Orozco</LastName>
<ForeName>Clotilde</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Department of Research Unit in Clinical Epidemiology, Medical Unit of High Specialty, Specialties Hospital of the Western Medical Center, Mexican Institute of Social Security, Guadalajara 44349, Jalisco, Mexico. clotilde.fuentes@gmail.com.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2015</Year>
<Month>04</Month>
<Day>29</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Iran</Country>
<MedlineTA>Urol J</MedlineTA>
<NlmUniqueID>101286676</NlmUniqueID>
<ISSNLinking>1735-1308</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D065087">Acetylcholine Release Inhibitors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.4.24.69</RegistryNumber>
<NameOfSubstance UI="D019274">Botulinum Toxins, Type A</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="CommentIn">
<RefSource>Urol J. 2015 Mar-Apr;12(2):2111-3</RefSource>
<PMID Version="1">25923159</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="CommentIn">
<RefSource>Urol J. 2015 Mar-Apr;12(2):2114</RefSource>
<PMID Version="1">26121772</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D065087">Acetylcholine Release Inhibitors</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019274">Botulinum Toxins, Type A</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004305">Dose-Response Relationship, Drug</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005500">Follow-Up Studies</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015552">Injections, Intralesional</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010410">Penile Erection</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010411">Penile Induration</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011446">Prospective Studies</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="received">
<Year>2015</Year>
<Month>01</Month>
<Day>10</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted">
<Year>2015</Year>
<Month>02</Month>
<Day>26</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez">
<Year>2015</Year>
<Month>4</Month>
<Day>30</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed">
<Year>2015</Year>
<Month>4</Month>
<Day>30</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2016</Year>
<Month>1</Month>
<Day>29</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>epublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">25923158</ArticleId>
<ArticleId IdType="pii">2894/954</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>